ESKATA Drug Patent Profile

Which patents cover Eskata, and what generic alternatives are available?

Eskata is a drug marketed by Aclaris and is included in one NDA. There are five patents protecting this drug.

This drug has nineteen patent family members in sixteen countries.

The generic ingredient in ESKATA is hydrogen peroxide. There are fifty-three drug master file entries for this compound. Additional details are available on the hydrogen peroxide profile page.

DrugPatentWatch^® Generic Entry Outlook for Eskata

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 21, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ESKATA

International Patents:	19
US Patents:	5
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	83
Patent Applications:	3,000
What excipients (inactive ingredients) are in ESKATA?	ESKATA excipients list
DailyMed Link:	ESKATA at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ESKATA

NDA:

209305

Dosage:

SOLUTION;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ESKATA

ESKATA is protected by five US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No			Y
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No			Y
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No			Y
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017		DISCN	Yes	No			Y

Expired US Patents for ESKATA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Aclaris	ESKATA	hydrogen peroxide	SOLUTION;TOPICAL	209305-001	Dec 14, 2017

International Patents for ESKATA

When does loss-of-exclusivity occur for ESKATA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

European Patent Office

Israel

Japan

Mexico

Poland

Portugal

Russian Federation

Singapore

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ESKATA around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	3134061
New Zealand	527673	Composition comprising at least 23% hydrogen peroxide for removal of acrochordons, aka skin tags
South Korea	20170029413	과산화물 제제 및 이를 사용하기 위한 방법 및 어플리케이터 (PEROXIDE FORMULATIONS AND METHODS AND APPLICATORS FOR USING THE SAME)
Singapore	11201608775X	PEROXIDE FORMULATIONS AND METHODS AND APPLICATORS FOR USING THE SAME
Japan	6622217

Supplementary Protection Certificates for ESKATA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2523731	2020/020	Ireland		PRODUCT NAME: OSILODROSTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING OSILODROSTAT DIHYDROGEN PHOSPHATE.; REGISTRATION NO/DATE: EU/1/19/1407 20200113
2523731	LUC00159	Luxembourg		PRODUCT NAME: OSILODROSTAT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, Y COMPRIS LE DIHYDROGENOPHOSPHATE D'OSILODROSTAT; AUTHORISATION NUMBER AND DATE: EU/1/19/1407 20200113
2523731	CR 2020 00025	Denmark		PRODUCT NAME: OSILODROSTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER OSILODROSTATDIHYDROGENFOSFAT; REG. NO/DATE: EU/1/19/1407 20200113
2787345	CR 2016 00055	Denmark		PRODUCT NAME: MIGALASTAT ELLER ET SALT HERAF, HERUNDER HYDROGENKLORIDSALTET; REG. NO/DATE: EU/1/15/1082 20160531
3106463	SPC/GB20/013	United Kingdom		PRODUCT NAME: LAROTRECITINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PARTICULARLY LAROTRECITINIB SULFATE INCLUDING LAROTRECITINIB HYDROGEN SULFATE; REGISTERED: UK EU/1/19/1385(NI) 20190923; UK PLGB 00010/0741 20190923; UK PLGB 00010/0742 20190923; UK PLGB 00010/0743 20190923

ESKATA Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

ESKATA (hydrogen peroxide topical solution, 40%), formerly developed by Aclaris Therapeutics, is a prescription drug indicated for the topical treatment of raised seborrheic keratoses. Aclaris Therapeutics was acquired by Allergan in June 2018 for approximately $300 million upfront plus potential milestone payments, signaling significant investor confidence in ESKATA’s commercial potential [1]. The acquisition aimed to bolster Allergan’s dermatology portfolio.

What is the Current Market Status of ESKATA?

ESKATA received U.S. Food and Drug Administration (FDA) approval on July 24, 2018, for the treatment of moderate to severe facial seborrheic keratoses in adult patients [2]. The drug is administered by a healthcare professional. Its approval marked a significant advancement as it was the first and only FDA-approved topical treatment for this specific dermatological condition.

The market for seborrheic keratoses treatment is substantial. Seborrheic keratoses are benign epidermal neoplasms that are extremely common, affecting an estimated 50% of adults over 50 years old [3]. While often asymptomatic, their cosmetic appearance can cause significant distress and impact quality of life for many patients. Prior to ESKATA, treatment options were primarily procedural, including cryotherapy, curettage, electrodessication, and surgical excision. These methods carry risks of scarring, pigmentation changes, and recurrence, and often require multiple treatment sessions [4].

ESKATA's mechanism of action involves the delivery of a high concentration of hydrogen peroxide directly to the lesion. This causes localized chemical ablation of the abnormal cells comprising the seborrheic keratosis [5]. Clinical trials demonstrated significant lesion reduction and clearance rates. For instance, in Phase III trials, approximately 54% to 62% of lesions treated with ESKATA achieved complete clearance after one or two treatments, compared to 5% to 13% for the vehicle control group [6].

The market positioning of ESKATA centers on its non-invasive nature and in-office administration, offering a potentially more convenient and predictable treatment outcome than traditional procedural methods, particularly for patients with multiple lesions or those seeking to avoid scarring.

What are the Key Competitive Factors Influencing ESKATA's Market Share?

The competitive landscape for seborrheic keratosis treatment is multifaceted, encompassing both established procedural methods and emerging pharmaceutical agents.

Procedural Treatments:

• Cryotherapy: This involves freezing the lesions with liquid nitrogen. It is widely available, relatively inexpensive, and often effective for individual lesions. However, it can lead to hypopigmentation or hyperpigmentation and blistering. Multiple treatments are often necessary [4].
• Curettage and Electrodesiccation: These surgical methods physically remove the lesion and then use heat to stop bleeding and destroy any remaining abnormal cells. They are effective but can result in scarring and require local anesthesia [4].
• Surgical Excision: This involves cutting out the lesion. It is generally reserved for larger or atypical lesions and always results in a scar.

These procedural options represent a significant baseline competition. They are often performed by dermatologists and plastic surgeons, are generally covered by insurance for cosmetic concerns in specific instances, and are well-understood by both practitioners and patients. The cost-effectiveness of these procedures, especially for single or few lesions, remains a strong competitive advantage.

Pharmaceutical Competitors:

The development of pharmaceutical treatments for benign skin lesions is an evolving area. While ESKATA was the first FDA-approved topical agent specifically for seborrheic keratoses, other agents have been investigated or are in development for similar indications or broader benign skin lesions.

• Topical Agents for Other Benign Lesions: Compounds investigated for actinic keratoses or other superficial skin lesions could potentially be explored for seborrheic keratoses off-label or in future indications. Examples include topical retinoids and other ablative agents.
• Emerging Therapies: The pharmaceutical industry continues to research novel topical formulations and delivery systems. While specific direct competitors to ESKATA for seborrheic keratoses are limited by its unique approval status, the broader field of cosmetic dermatology is constantly evolving.

The primary competitive advantage of ESKATA lies in its targeted indication, novel mechanism of action as a topical prescription drug, and demonstrated efficacy in clinical trials for lesion clearance. Its key differentiators are:

• Prescription Status: Positions it as a medical treatment rather than a cosmetic procedure.
• In-Office Administration: Provides controlled application and reduces the risk of off-target effects compared to some at-home treatments.
• Targeted Efficacy: Demonstrated significant clearance rates in clinical studies for moderate to severe seborrheic keratoses.
• Reduced Scarring Potential: Clinical data suggests a lower risk of scarring compared to some ablative procedures.

However, the cost of ESKATA, the need for physician administration, and the ongoing availability and familiarity of procedural treatments present significant competitive hurdles. Payor coverage and reimbursement policies are also critical factors influencing market adoption and physician prescribing patterns.

What is the Financial Trajectory and Revenue Generation Potential of ESKATA?

Following its acquisition by Allergan, ESKATA's financial trajectory is tied to Allergan's commercialization strategy and market penetration efforts. Financial projections for ESKATA are influenced by several key revenue drivers and cost factors.

Revenue Drivers:

• Market Penetration: The success of ESKATA hinges on the adoption rate by dermatologists and their willingness to incorporate it into their treatment protocols for seborrheic keratoses. This is influenced by physician education, marketing efforts, and perceived patient benefit.
• Prescription Volume: The number of patients seeking treatment for seborrheic keratoses and the proportion of those prescribed ESKATA directly impact revenue. The prevalence of seborrheic keratoses (affecting approximately 50% of adults over 50) indicates a large potential patient pool [3].
• Pricing Strategy: Allergan sets the price of ESKATA. The drug is administered in a clinical setting, and its pricing will reflect the drug cost, administration fees, and the perceived value compared to existing treatments.
• Reimbursement and Payer Coverage: The extent to which insurance providers cover ESKATA is a critical factor. While it is a prescription drug, cosmetic indications can face challenges with reimbursement. Allergan's efforts to secure favorable formulary placement and reimbursement for medically necessary or aesthetically significant cases will be paramount.
• Geographic Expansion: While initially launched in the U.S., potential expansion into international markets would broaden the revenue base.

Cost Factors:

• Manufacturing and Supply Chain: Costs associated with producing ESKATA at scale.
• Sales and Marketing: Investment in detailing, advertising, and promotional activities to educate healthcare professionals and consumers.
• Research and Development (R&D): Ongoing investment in post-marketing studies, potential label expansions (e.g., other body sites), or next-generation formulations.
• Regulatory Compliance: Costs associated with maintaining regulatory approvals.

Financial Performance (Post-Acquisition):

Detailed, publicly disclosed revenue figures specifically for ESKATA post-acquisition are not readily available as it is integrated into Allergan's broader dermatology segment reporting. However, Allergan's acquisition valuation of Aclaris Therapeutics ($300 million upfront plus milestones) suggests a significant expected return on investment. Analyst reports and investor calls surrounding the acquisition anticipated ESKATA to generate substantial revenue, potentially hundreds of millions of dollars annually, within its first few years on the market [1].

The financial trajectory will be characterized by initial growth driven by market entry and physician adoption, followed by sustained revenue generation if ESKATA can establish a strong market share against established procedural treatments and any future pharmaceutical competitors. Pricing, reimbursement, and effective physician detailing will be key determinants of its ultimate financial success.

What are the Key Regulatory and Intellectual Property Considerations for ESKATA?

The regulatory and intellectual property landscape is crucial for ESKATA's commercial viability and long-term market protection.

Regulatory Considerations:

• FDA Approval: ESKATA's FDA approval on July 24, 2018, for moderate to severe facial seborrheic keratoses in adults is the primary regulatory milestone [2]. This approval is based on a rigorous review of safety and efficacy data from clinical trials.
• Prescription Status: The drug is classified as a prescription-only medication, requiring administration by a healthcare professional. This dictates its distribution channels and prescribing patterns.
• Labeling and Indications: The approved indication is specific to the face. Any expansion to other body sites would require supplemental New Drug Applications (sNDA) and further clinical data.
• Post-Marketing Surveillance: Like all approved drugs, ESKATA is subject to post-marketing surveillance to monitor for adverse events and ensure continued safety and effectiveness.
• Manufacturing Standards: Production must adhere to Current Good Manufacturing Practices (cGMP) to ensure product quality and consistency.
• International Regulatory Bodies: For global market entry, ESKATA would need to obtain approvals from regulatory agencies in each target country (e.g., European Medicines Agency (EMA) in Europe, Health Canada).

Intellectual Property Considerations:

• Patents: The core intellectual property protecting ESKATA includes patents covering its composition of matter, methods of formulation, and methods of treatment.
  • Aclaris Therapeutics held a portfolio of patents related to ESKATA and its therapeutic applications.
  • Upon acquisition, Allergan assumed ownership of these patents.
  • The lifespan of these patents is critical. U.S. patent protection typically lasts 20 years from the filing date, but patent term extensions can be granted for regulatory delays.
  • The exact expiration dates of key ESKATA patents are not publicly disclosed in detail but are crucial for forecasting the timeline to potential generic competition. Pharmaceutical companies often seek multiple layers of patent protection, including method-of-use patents and formulation patents, to extend market exclusivity.
• Exclusivity Periods: In addition to patent protection, regulatory exclusivities granted by the FDA (e.g., Hatch-Waxman exclusivities) can provide market protection independent of patents. For a new chemical entity (NCE), this is typically 5 years. For a new indication or formulation, it can be 3 years. The specific exclusivities granted to ESKATA will influence its period of market dominance before generic entry.
• Freedom to Operate (FTO): Allergan would have conducted extensive FTO analyses to ensure that the commercialization of ESKATA does not infringe on existing patents held by other entities.
• Generic Competition: Once the relevant patents and regulatory exclusivities expire, generic manufacturers can seek FDA approval to market their own versions of ESKATA. This typically leads to significant price erosion and a substantial decrease in market share for the branded product. The timeline to generic entry is a key factor in valuing the long-term revenue stream of ESKATA.

The strength and breadth of ESKATA's intellectual property portfolio, coupled with regulatory hurdles for generic entrants, will dictate the duration of its market exclusivity and profitability.

What are the Key Performance Indicators (KPIs) for Monitoring ESKATA's Market Success?

Monitoring key performance indicators (KPIs) is essential for assessing ESKATA's market performance and informing strategic adjustments.

Prescription Data:

• New Prescriptions (NRx): Tracks the number of first-time prescriptions written for ESKATA. This indicates physician adoption and patient initiation.
• Total Prescriptions (TRx): Represents the overall number of prescriptions filled, including new and refill prescriptions. This reflects ongoing patient use and market penetration.
• Prescriber Count: The number of unique healthcare providers prescribing ESKATA. An increasing prescriber base suggests broader market acceptance.
• Prescriber Segment Analysis: Identifying which specialties (e.g., dermatologists, general practitioners) are prescribing ESKATA, and the volume of prescriptions from each segment.

Market Share and Competitive Positioning:

• Market Share within Seborrheic Keratosis Treatment: The percentage of total seborrheic keratosis treatments (both procedural and pharmaceutical) that are accounted for by ESKATA.
• Share of Voice (SOV): Measures brand visibility and marketing presence relative to competitors in professional and patient-facing communications.
• Competitive Script Volume: Tracking prescription data for alternative treatments to benchmark ESKATA's performance against direct and indirect competitors.

Financial Metrics:

• Net Sales: The revenue generated from ESKATA sales after accounting for returns, rebates, and discounts.
• Average Selling Price (ASP): The effective price per unit sold, reflecting pricing strategies and payer negotiations.
• Gross Profit Margin: The profitability of ESKATA sales after deducting the cost of goods sold.
• Return on Investment (ROI) for Sales & Marketing Spend: Evaluating the effectiveness of promotional activities in driving sales.

Patient and Physician Feedback:

• Patient Adherence Rates: The proportion of patients who complete their prescribed course of treatment. This can be indirectly gauged through refill rates.
• Physician Satisfaction and Perceptions: Feedback from healthcare professionals regarding ESKATA's efficacy, ease of use, and patient outcomes. This can be gathered through surveys and advisory boards.
• Adverse Event Reporting: Monitoring the frequency and severity of reported side effects, which can impact physician confidence and prescribing.

Payer and Reimbursement Landscape:

• Payer Coverage Rates: The percentage of insurance plans that cover ESKATA.
• Prior Authorization Requirements: The frequency with which prior authorization is required, which can be a barrier to access.
• Co-Pay Amounts: The out-of-pocket cost for patients, influencing affordability and demand.

These KPIs provide a comprehensive view of ESKATA's performance, enabling Allergan to identify areas of strength, address challenges, and optimize its commercial strategy for sustained market success.

Key Takeaways

ESKATA represents a significant pharmaceutical advancement in the treatment of seborrheic keratoses, offering a topical, prescription-based alternative to traditional procedural interventions. Following its acquisition by Allergan for a substantial upfront payment, its market trajectory is contingent on effective commercialization, physician adoption, and favorable payer coverage. The drug's unique mechanism of action and demonstrated efficacy in clinical trials position it to capture a meaningful share of the large seborrheic keratosis market. However, competition from established procedural treatments and the potential for future generic entry necessitate robust intellectual property protection and strategic market positioning. Key performance indicators, encompassing prescription data, market share, financial metrics, and stakeholder feedback, are critical for monitoring ESKATA's ongoing success and informing strategic decisions.

FAQs

1. What is the primary indication for ESKATA? ESKATA is indicated for the topical treatment of moderate to severe facial seborrheic keratoses in adult patients.

2. How is ESKATA administered? ESKATA is administered by a healthcare professional in an office setting.

3. What are the main advantages of ESKATA compared to existing seborrheic keratosis treatments? ESKATA offers a non-invasive, topical prescription option with a targeted mechanism of action, potentially reducing the risk of scarring compared to some procedural treatments.

4. What factors are critical for ESKATA's long-term financial success? Key factors include physician adoption, payer reimbursement, effective marketing, market penetration against established procedures, and the duration of patent and regulatory exclusivity.

5. When can generic versions of ESKATA be expected? The availability of generic versions depends on the expiration dates of ESKATA's relevant patents and regulatory exclusivities, which are not publicly detailed but are critical for determining the timeline to generic competition.

---

Citations

[1] Aclaris Therapeutics. (2018, June 4). Allergan to acquire Aclaris Therapeutics, Inc. Business Wire. [2] U.S. Food & Drug Administration. (2018, July 24). FDA approves Eskata (hydrogen peroxide topical solution, 40%) for the treatment of moderate to severe facial seborrheic keratosis. [Press release]. [3] Robert, L., & Barnhill, R. L. (2008). Seborrheic keratosis. In L. R. Goldman & F. B. Christensen (Eds.), Dermatology in Primary Care (pp. 167-172). McGraw-Hill. [4] Jones, S. M., & Rieder, R. M. (2015). Seborrheic keratoses. In W. B. Lish (Ed.), Dermatology (pp. 777-780). Elsevier Saunders. [5] Aclaris Therapeutics. (2017). ESKATA (hydrogen peroxide topical solution, 40%) prescribing information. [6] Goldenberg, G., et al. (2017). A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Hydrogen Peroxide Topical Solution, 40%, for the Treatment of Seborrheic Keratoses. Journal of Drugs in Dermatology, 16(4), 346-352.